Amgen's Nplate® Maintains Platelet Counts For More Than Five Years In Adults With Chronic ITP
Links shared publicly online about this topic.
- 672total visits
Amgen's Nplate® Maintains Platelet Counts For More Than Five Years In Adults With Chronic ITP
View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2010 at 12:05 pm By:
Amgen's Nplate® Maintains Platelet Counts For More Than Five Years In Adults With Chronic ITP http://mnt.to/3NGD #pharma #pharmaceutical
Also Shared By:
Amgen will buy KAI Pharmaceuticals for $315 million - latimes.com
latimes.com — “Biotech firm Amgen will pay $315 million to buy KAI Pharmaceuticals, a company that is developing a drug to treat secondary hyperparathyroidism, a common side effect of kidney disease.” View full resource at latimes.com
Most Recently Shared on April 10, 2012 at 11:06 pm By:
Drugs and Devices OW OW Health
Amgen will buy KAI Pharmaceuticals for $315 million - Los Angeles Times: Amgen will buy KAI Pharmaceutical... http://t.co/gsvXoRkg #drug
Postmenopausal Osteoporosis Phase 3 Trial Starts, Say Amgen And UCB
medicalnewstoday.com — “Osteoporosis affects more than 75 million people, with women being four times more at risk of developing the disease than men. Osteoporosis is a chronic, progressive and systemic disease, whereby” View full resource at medicalnewstoday.com
Most Recently Shared on April 9, 2012 at 7:05 pm By:
Postmenopausal Osteoporosis Phase 3 Trial Starts, Say Amgen And UCB http://t.co/0xXcY4vO #menopause
Choosing Wisely: 5 Things Physicians and Patients Should Question http://t.co/y2UEToCi via @ASCO
choosingwisely.org — “Choosing Wisely: 5 Things Physicians and Patients Should Question http://t.co/y2UEToCi via @ASCO” View full resource at choosingwisely.org
Most Recently Shared on April 5, 2012 at 3:52 pm By:
Robert S. Miller, MD Internist, Oncologist, Physician, and Doctor
Choosing Wisely: 5 Things Physicians and Patients Should Question http://t.co/y2UEToCi via @ASCO
Amgen Psoriasis Candidate Impresses - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: Results from the phase II study showed that brodalumab achieved its primary endpoint.” View full resource at finance.yahoo.com
Most Recently Shared on April 5, 2012 at 8:45 am By:
Amgen Psoriasis Candidate Impresses: Results from the phase II study showed that brodalumab achieved its primary... http://t.co/Ub5c6zuR
Amgen Psoriasis Candidate Impresses - Analyst Blog - NASDAQ.com
community.nasdaq.com — “The New England Journal of Medicine recently published positive phase II data on Amgens ( AMGN ) psoriasis candidate, brodalumab” View full resource at community.nasdaq.com
Most Recently Shared on April 5, 2012 at 8:45 am By:
Amgen Psoriasis Candidate Impresses - Analyst Blog: The New England Journal of Medicine recently published posit... http://t.co/B9R3O0cL
INTERVIEW: AstraZeneca R&D Head Predicts More Collaborative Deals - WSJ.com
online.wsj.com — “INTERVIEW: AstraZeneca R&D Head Predicts More Collaborative Deals - WSJ.com” View full resource at online.wsj.com
Most Recently Shared on April 4, 2012 at 12:18 pm By:
reading @stenstovall on AZ #collaboration with @amgen http://t.co/8qssjUoW
AstraZeneca hunting more deals like Amgen tie-up - Courant.com
courant.com — “LONDON (Reuters) - AstraZeneca is seeking more deals to fill its sparse drug pipeline like the one just signed with Amgen , but is not in the market for the kind of large acquisition some investors have speculated about.” View full resource at courant.com
Most Recently Shared on April 3, 2012 at 5:18 pm By:
John Carroll Health Communicator
AstraZeneca talks acquisitions, deals with @ReutersBenHir http://t.co/T5qAFgpJ?
AstraZeneca investors encouraged by partnership with US group Amgen, but FTSE slips back | Business | guardian.co.uk
guardian.co.uk — “Astra and Amgen to collaborate on five biotech drugs, with Astra paying $50m upfront” View full resource at guardian.co.uk
Most Recently Shared on April 3, 2012 at 12:49 pm By:
A roundup of analyst comments on AstraZeneca-Amgen collaboration, from the Guardian http://t.co/bejxWNCX #pharma $AZN $AMGN
Amgen, AstraZeneca to Work on Inflammation Drugs - WSJ.com
online.wsj.com — “Amgen and AstraZeneca reached a deal to jointly develop and commercialize five inflammatory disease treatments in Amgen's portfolio.” View full resource at online.wsj.com
Most Recently Shared on April 2, 2012 at 9:36 pm By:
Amgen, AstraZeneca to Work on Inflammation Drugs http://t.co/KHcCwwAf
AstraZeneca - AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio
astrazeneca.com — “AstraZeneca, AMGEN” View full resource at astrazeneca.com
Most Recently Shared on April 2, 2012 at 8:21 pm By:
AZ & @Amgen announce #collaboration to develop & commercialise #inflammation portfolio http://t.co/39Vxeck9
Research duo say that far too many preclinical cancer study results are just plain wrong
medicalxpress.com — “(Medical Xpress) -- C. Glenn Begley, formerly head of cancer research at pharmaceutical giant Amgen and Lee M. Ellis a cancer researcher at the University of Texas, have published a paper together in Nature that is sure to cause a storm of controversy in the cancer research community. They say they ...” View full resource at medicalxpress.com
Most Recently Shared on March 29, 2012 at 3:06 pm By:
Richard G. Lanzara Health Professional
...far too many preclinical cancer study results are just plain wrong - http://t.co/lrLJCHlb #science #research #medicine #cancer
Sloppy Science. In the Pipeline:
pipeline.corante.com — “Sloppy Science. In the Pipeline:” View full resource at pipeline.corante.com
Most Recently Shared on March 29, 2012 at 1:57 pm By:
Luke Timmerman Health Communicator
Good piece by @sxbegle RT @Dereklowe: Too many groundbreaking cancer results turn out to be wrong: Amgen says 90% fail http://t.co/9aNd4raG
Researcher: Many cancer ‘discoveries’ inaccurate | The Columbus Dispatch
dispatch.com — “NEW YORK — A former researcher at Amgen Inc. has found that many basic studies on cancer — a high proportion of them from university labs — are unreliable, with grim consequences for producing new medicines.” View full resource at dispatch.com
Most Recently Shared on March 29, 2012 at 1:54 pm By:
Tom Heston, MD Physician, Doctor, and Family Medicine Doctor
Researcher: Many cancer 'discoveries' inaccurate - Columbus Dispatch http://t.co/Pgq3oZGy #medicine
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 7:47 pm By:
Amgen Loses Monopoly on Drug for Dialysis Patients - http://t.co/O6kMuGDy #pharma
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 6:19 pm By:
Daniel Kraft Health Executive, Physician, Doctor, Pediatrician, and Internist
NYTimes: F.D.A. Approves New Anemia Drug http://t.co/WJKYbgWZ
Advertisement
Rich Meyer
@richmeyer
Amgen Loses Monopoly on Drug for Dialysis Patients - http://t.co/O6kMuGDy #pharma
1 year ago...